ICU Medical (ICUI) investor relations material

Macro environment and business outlook

• Hospital admissions remain strong with no slowdown observed; demand and utilization are stable and in line with guidance assumptions.

• The outlook for the rest of the year is consistent, with no significant swings expected.

• Portfolio strategy focuses on building a coherent offering of pumps, consumables, and IV solutions, not just growth rates.

• Stable census and continued niche market creation are expected to support ongoing growth.

IV systems and competitive positioning

• IV systems business has grown robustly, driven mainly by competitive wins and some install base upgrades.

• The upgrade cycle for LVP pumps is just beginning and will start in earnest next year, with a 7–10 year device life.

• Consumables growth from upgrades is limited, as most are already in place; competitive wins offer more consumables upside.

• The competitive environment remains active, with significant opportunities in both the U.S. and global markets for equipment refresh.

Regulatory and product development

• Progress is being made on syringe pump FDA re-filing, with confidence in submission this year and a typical 6–9 month review cycle.

• CADD development continues at lower priority, trailing Medfusion, but requirements are understood.

• LifeShield software platform offers enterprise-wide, cloud-based drug library management and interoperability, with ongoing efforts to demonstrate value and re-profitize software.